Michael Mahoney; Chairman of the Board, President, Chief Executive Officer; Boston Scientific Corp Daniel Brennan; Chief Financial Officer, Executive Vice President; Boston Scientific Corp Kenneth ...

Executive Vice President and Chief Financial Officer, Daniel J. Brennan, recently engaged in a series of stock transactions, according to a recent SEC filing. The transactions come as the company, now ...

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...

Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

CFO Daniel Brennan reported Q4 consolidated revenue of $4.561 billion, representing 22.4% growth compared to Q4 2023. The company achieved a full-year adjusted operating margin of 27%, with ...

Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment ...

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted significant advancements ...